suPAR Cut-Offs for Risk Stratification in Patients With Symptoms of COVID-19

Autor: Christian Rasmussen, Ove Andersen, Santeri Seppälä, Thomas Kallemose, Line Jee Hartmann Rasmussen, Jens Tingleff, Jan O. Nehlin, Sanaá Elmajdoubi, Izzet Altintas, Mette Bendtz Lindstrøm, Nora Olsen El Caidi, Harri Hyppölä, Klaus Tjelle Kristiansen, Marius Ahm Stauning, Jesper Eugen-Olsen, Hejdi Gamst-Jensen

Publikováno v: Biomarker Insights
Biomarker Insights, Vol 16 (2021)
Altintas, I, Eugen-Olsen, J, Seppälä, S, Tingleff, J, Stauning, M A, El Caidi, N O, Elmajdoubi, S, Gamst-Jensen, H, Lindstrøm, M B, Rasmussen, L J H, Kristiansen, K T, Rasmussen, C, Nehlin, J O, Kallemose, T, Hyppölä, H & Andersen, O 2021, ' suPAR Cut-Offs for Risk Stratification in Patients With Symptoms of COVID-19 ', Biomarker Insights, vol. 16, pp. 1-12 . https://doi.org/10.1177/11772719211034685

Objectives: Elevated soluble urokinase Plasminogen Activator Receptor (suPAR) is a biomarker associated with adverse outcomes. We aimed to investigate the associations between plasma suPAR levels (testing the cut-offs ⩽4, 4-6, and ⩾6 ng/mL) with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::654574ad00defc92b174fb2b255d9d93
http://europepmc.org/articles/PMC8371731